Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.

Abstract:

INTRODUCTION:Neisseria meningitidis causes invasive meningococcal disease (IMD), with the highest incidence observed in infants and young children. Meningococcal serogroups A, B, C, W, X, and Y account for almost all IMD cases worldwide. Available meningococcal vaccines targeting serogroups A, C, W, and Y (MenACWY) include those conjugated to diphtheria toxoid (MenACWY-D), diphtheria protein cross-reactive material 197 (MenACWY-CRM197), and tetanus toxoid (MenACWY-TT). MenACWY-TT is indicated for use starting at 6 weeks of age. AREAS COVERED:This review discusses data from the four primary studies assessing MenACWY-TT safety and immunogenicity in infants, which evaluated a variety of dosing schedules, short-term and long-term outcomes, and impact of coadministration on the immunogenicity of routine childhood vaccines. Remaining gaps in the field are addressed. EXPERT OPINION:Robust data support the use of MenACWY-TT in infants starting as early as 6 weeks of age. MenACWY-TT was safe and well tolerated in infants, was immunogenic after priming and booster, and demonstrated persistent immunogenicity. Lower persistence for serogroup A relative to other serogroups based on serum bactericidal assays (SBAs) using human complement appears to be a class effect of MenACWY conjugate vaccines. Correlates of protection other than SBA are being explored, including immunologic responses associated with different carrier proteins.

journal_name

Expert Rev Vaccines

authors

Martinón-Torres F,Serra L,Safadi MAP

doi

10.1080/14760584.2020.1745070

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

313-325

issue

4

eissn

1476-0584

issn

1744-8395

journal_volume

19

pub_type

杂志文章
  • Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination:a meta-analysis.

    abstract:BACKGROUND:Despite high 1-dose vaccination coverage, breakthrough varicella infections still occur. Therefore, 2-dose vaccination is recommended to enhance the immune response to the virus. However, the reported incremental vaccine effectiveness (VE) of 2-dose vaccination varies widely among studies. METHODS:To determ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14760584.2018.1433999

    authors: Yin M,Xu X,Liang Y,Ni J

    更新日期:2018-04-01 00:00:00

  • Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy.

    abstract::Peanut-allergen hypersensitivity reactions, which can result in anaphylactic episodes and death, affect approximately 1% of the general population. Currently, strict avoidance of allergenic food is the only available treatment for this food-induced allergic reaction; however, the innocuous presence of trace amounts of...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.119

    authors: Miller DS,Brown MP,Howley PM,Hayball JD

    更新日期:2012-12-01 00:00:00

  • Development of cowpea mosaic virus-based vectors for the production of vaccines in plants.

    abstract::Plant viruses are emerging as an attractive alternative to stable genetic transformation for the expression of foreign proteins in plants. The main advantages of using this strategy are that viral genomes are small and easy to manipulate, infection of plants with modified viruses is simpler and quicker than the regene...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.5.687

    authors: Cañizares MC,Lomonossoff GP,Nicholson L

    更新日期:2005-10-01 00:00:00

  • Strategies for inducing effective neutralizing antibody responses against HIV-1.

    abstract::Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine available against HIV-1. Currently, substantial efforts are devoted to the development of vaccines aimed at inducing broadly neutralizing antibodies (bNAbs), which are capable of neutralizing most HIV-1 strains. All bNAb...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1690458

    authors: Del Moral-Sánchez I,Sliepen K

    更新日期:2019-11-01 00:00:00

  • Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines.

    abstract:OBJECTIVES:We evaluated memory responses and antibody persistence to diphtheria-toxoid, tetanus-toxoid, whole-cell-pertussis (DTwP), and Hepatitis-B vaccines in HIV-unexposed, HIV-exposed-uninfected and HIV-infected children previously randomized to initiate time-limited ART at 6-10 weeks (ART-Immed) or when clinically...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14760584.2019.1547195

    authors: Simani OE,Izu A,Nunes MC,Violari A,Cotton MF,Van Niekerk N,Adrian PV,Madhi SA

    更新日期:2019-01-01 00:00:00

  • Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.

    abstract::Infections of humans with Bacillus anthracis are an issue with respect to the biothreat both to civilians and military personnel, infections of individuals by infected livestock in endemic regions and, recently, infections of intravenous drug users injecting anthrax-contaminated heroin. Existing vaccination regimens a...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.981533

    authors: Altmann DM

    更新日期:2015-03-01 00:00:00

  • Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.

    abstract::Serogroup B Neisseria meningitidis is the leading cause of meningococcal disease in developed countries. There is currently no vaccine offering wide-ranging protection. Development of a serogroup B polysaccharide-based vaccine has been hindered by potential risks of autoantibodies that cross-react with glycosylated ho...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.116

    authors: Bai X,Borrow R

    更新日期:2010-10-01 00:00:00

  • Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.

    abstract::Adolescents have the highest rates of meningococcal carriage and transmission. Interrupting the adolescent habitat in order to reduce carriage and transmission within adolescents and to other age groups could help to control meningococcal disease at a population level. Compared to immunization strategies restricted to...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1130628

    authors: Vetter V,Baxter R,Denizer G,Sáfadi MA,Silfverdal SA,Vyse A,Borrow R

    更新日期:2016-05-01 00:00:00

  • Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

    abstract::Recombinant modified vaccinia virus Ankara (MVA) is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vac...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.4

    authors: Rimmelzwaan GF,Sutter G

    更新日期:2009-04-01 00:00:00

  • TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.

    abstract::Vaccination has been a successful tool in the protection against many infectious diseases, and recent advances in biotechnology have created new techniques and strategies to produce safe and efficacious vaccines for human use. However, developing a protective vaccine against malaria has been a challenge. In this artic...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.60

    authors: Coban C,Horii T,Akira S,Ishii KJ

    更新日期:2010-07-01 00:00:00

  • Peptidomimetics: modifying peptides in the pursuit of better vaccines.

    abstract::Peptide vaccines represent a potential strategy for the prevention and treatment of pathogenic diseases, cancers and autoimmune disorders; their low cost, ease of synthesis and inherent safety are all attractive features. However, they have remained largely unsuccessful owing to low immunogenicity, predominantly stemm...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.161

    authors: Croft NP,Purcell AW

    更新日期:2011-02-01 00:00:00

  • Live-attenuated Shigella vaccines.

    abstract::Several live-attenuated Shigella vaccines, with well-defined mutations in specific genes, have shown great promise in eliciting significant immune responses when given orally to volunteers. These responses have been measured by evaluating antibody-secreting cells, serum antibody levels and fecal immunoglobulin A to ba...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.5.669

    authors: Venkatesan MM,Ranallo RT

    更新日期:2006-10-01 00:00:00

  • 11th Annual Conference on Vaccine Research.

    abstract::The 11th Annual Conference on Vaccine Research, hosted by the National Foundation for Infectious Disease, attracted approximately 450 leaders in the fields of epidemiology, health economics, immunology and vaccinology, making it the largest scientific meeting devoted exclusively to vaccine research and technology. The...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/14760584.7.6.721

    authors: O'Brien J

    更新日期:2008-08-01 00:00:00

  • Challenges of Global Vaccine Development.

    abstract::The Keystone Symposia conference, Challenges of Global Vaccine Development, attracted approximately 440 scientists, physicians and students from all around the world. The conference goal was to share newly acquired knowledge regarding vaccine-induced immunity, novel technologies, childhood vaccines, preclinical models...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/14760584.7.1.21

    authors: Gudmundsdotter L,Hallengärd D

    更新日期:2008-02-01 00:00:00

  • Efficacy, safety, and formulation issues of the combined vaccines.

    abstract::Introduction: Controlling the preventable infectious diseases is the main goal of vaccination. Among the vaccines, combined vaccines are of great importance for their social, public health, and economic values. It is stated that the combined vaccines are as efficient and safe as the monovalent vaccines. However, a con...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1843434

    authors: Tafreshi SH

    更新日期:2020-10-01 00:00:00

  • The Yin-Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation.

    abstract::The disease-fighting power of vaccines has defeated many pathogens and has been credited with global reduction of mortality and morbidity. However, most vaccine developments focus on the enhancement of effector responses with systemic inflammation and the consequences overlooked. Recent evidence shows that systemic in...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.882775

    authors: Tang DC,Nguyen HH

    更新日期:2014-03-01 00:00:00

  • An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

    abstract::With the exception of alum, emulsion-based vaccine adjuvants have been administered to far more people than any other adjuvant, especially since the 2009 H1N1 influenza pandemic. The number of clinical safety and immunogenicity evaluations of vaccines containing emulsion adjuvants has correspondingly mushroomed. In th...

    journal_title:Expert review of vaccines

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14760584.2013.811188

    authors: Fox CB,Haensler J

    更新日期:2013-07-01 00:00:00

  • Vaccines: facing complex problems with the promise of immunology.

    abstract::Highly renowned in the vaccines world, Stanley A. Plotkin has worked at many leading institutions throughout his career, and is Emeritus Professor of the University of Pennsylvania and Adjunct Professor of the Johns Hopkins University. In 1991, Plotkin joined Sanofi Pasteur and worked there from 1991 to 1997, and now ...

    journal_title:Expert review of vaccines

    pub_type: 面试

    doi:10.1586/14760584.2014.934678

    authors: Plotkin SA,Rees J

    更新日期:2014-08-01 00:00:00

  • Vaccination and healthy aging.

    abstract::The aging process in humans is associated with a decrease in immune function (immunosenescence) and an increase in comorbid disorders. When combined with environmental factors this can lead to an increased risk and severity of infectious diseases. Diseases in older adults (>/=70 years) tend to be more severe and have ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.26

    authors: Maggi S

    更新日期:2010-03-01 00:00:00

  • Pertussis: should we improve intensive care management or vaccination strategies?

    abstract::Bordetella pertussis, responsible for one of the oldest vaccine-preventable diseases in children, has resurged in North America, Europe, Latin America and many countries around the world. Despite new recommended vaccination strategies for adolescents, pregnant women and adults, mortality is still significant in develo...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.10.156

    authors: Ulloa-Gutierrez R,Boza R,Carvajal-Riggioni D,Baltodano A

    更新日期:2011-01-01 00:00:00

  • Ebola virus vaccines: an overview of current approaches.

    abstract::Ebola hemorrhagic fever is one of the most fatal viral diseases worldwide affecting humans and nonhuman primates. Although infections only occur frequently in Central Africa, the virus has the potential to spread globally and is classified as a category A pathogen that could be misused as a bioterrorism agent. As of t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.885841

    authors: Marzi A,Feldmann H

    更新日期:2014-04-01 00:00:00

  • Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans.

    abstract::Protection against acquisition of fully heterologous, neutralization-resistant SIV was achieved in rhesus monkeys with adenovirus/poxvirus vector-based vaccines. Protection against acquisition of infection required the inclusion of envelope antigens and correlated with the induction of binding antibodies against the E...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.12.21

    authors: Esparza J

    更新日期:2012-05-01 00:00:00

  • Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data.

    abstract:INTRODUCTION:Meningococcal disease has an incidence peak spread over several years during adolescence and young adulthood in the United States. Meningococcal serogroup B (MenB) vaccines have been introduced relatively recently and may help protect individuals in these age groups. Currently there is insufficient long-te...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1580579

    authors: Watson PS,Novy P,Bekkat-Berkani R,Strubbe F,Banzhoff A

    更新日期:2019-04-01 00:00:00

  • Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.

    abstract::Influenza inflicts significant global mortality and morbidity that can be combated by effective immunization. However, the protective efficacy of current vaccines is limited by both the significant antigenic diversity of the viral hemagglutinin protein and the capacity for rapid antigenic change. This necessitates glo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1068125

    authors: Wheatley AK,Kent SJ

    更新日期:2015-01-01 00:00:00

  • The potential of plants for the production and delivery of human papillomavirus vaccines.

    abstract::The available vaccines against human papillomavirus have some limitations such as low coverage due to their high cost, reduced immune coverage and the lack of therapeutic effects. Recombinant vaccines produced in plants (genetically engineered using stable or transient expression systems) offer the possibility to obta...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1037744

    authors: Rosales-Mendoza S,Govea-Alonso DO

    更新日期:2015-07-01 00:00:00

  • An overview of in silico vaccine design against different pathogens and cancer.

    abstract:INTRODUCTION:Due to overcome the hardness of the vaccine design, computational vaccinology is emerging widely. Prediction of T cell and B cell epitopes, antigen processing analysis, antigenicity analysis, population coverage, conservancy analysis, allergenicity assessment, toxicity prediction, and protein-peptide docki...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1794832

    authors: Kardani K,Bolhassani A,Namvar A

    更新日期:2020-08-01 00:00:00

  • Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.

    abstract::Several subtypes of influenza A viruses with pandemic potential are endemic in bird populations throughout Asia, Africa and the Middle East, and evidence suggests that these viruses are adapting to the mammalian host. As emphasized by the high mortality rate of humans infected with H5N1 viruses, this situation present...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.13.21

    authors: Barrett PN,Portsmouth D,Ehrlich HJ

    更新日期:2013-04-01 00:00:00

  • CpG DNA as a vaccine adjuvant.

    abstract::Synthetic oligodeoxynucleotides containing unmethylated CpG motifs act as immune adjuvants, accelerating and boosting antigen-specific antibody responses by up to 500-fold. CpG motifs promote the production of T-helper 1 and pro-inflammatory cytokines and induce the maturation/activation of professional antigen-presen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2.2.305

    authors: Klinman DM

    更新日期:2003-04-01 00:00:00

  • Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.

    abstract::Invasive meningococcal disease is a global public-health concern, with infants and adolescents bearing the majority of the disease burden. Vaccination is the most rational strategy to prevent meningococcal disease. Control of serogroup C disease has largely been achieved by the introduction of glycoconjugate meningoco...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.18

    authors: Pace D

    更新日期:2009-05-01 00:00:00

  • Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

    abstract::Although mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.166

    authors: Doroud D,Rafati S

    更新日期:2012-01-01 00:00:00